Certara, Inc. (NASDAQ:CERT) Receives $15.92 Consensus PT from Brokerages

Certara, Inc. (NASDAQ:CERT) has been given a consensus recommendation of “Hold” by the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $15.92.

A number of research analysts have recently weighed in on the company. Barclays cut their price objective on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Robert W. Baird reduced their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Finally, UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Friday, September 27th.

Certara Stock Up 1.1 %

Shares of CERT opened at $11.33 on Tuesday. The business’s 50 day moving average is $10.78 and its 200 day moving average is $12.07. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara has a 12-month low of $9.41 and a 12-month high of $19.87. The company has a market capitalization of $1.82 billion, a PE ratio of -56.65, a price-to-earnings-growth ratio of 5.86 and a beta of 1.52.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $95.51 million. During the same quarter last year, the business posted $0.06 earnings per share. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. Research analysts expect that Certara will post 0.28 earnings per share for the current fiscal year.

Institutional Trading of Certara

Institutional investors have recently bought and sold shares of the stock. Wasatch Advisors LP raised its stake in shares of Certara by 22.4% in the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after acquiring an additional 1,651,076 shares during the period. Geneva Capital Management LLC raised its position in Certara by 0.7% in the 3rd quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company’s stock worth $64,525,000 after purchasing an additional 37,392 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in Certara by 40.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock worth $45,691,000 after purchasing an additional 1,128,006 shares during the last quarter. State Street Corp lifted its stake in Certara by 3.4% in the third quarter. State Street Corp now owns 3,679,699 shares of the company’s stock worth $43,089,000 after purchasing an additional 122,411 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Certara by 9.7% during the second quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after buying an additional 273,095 shares during the period. 73.96% of the stock is currently owned by institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.